Enhancing therapeutic efficacy through localized radioimmunotherapy via intratumoral nanofluidic drug-eluting seed

World Health Organization estimated that in 2018 about 12% of women were diagnosed null with breast cancer, and 17% of them were found to be triple negative breast null cancers. Immunotherapy is currently one of the most appealing and promising cancer null treatments. However, conventional systemic administration of immunotherapeutics null can often lead to adverse side effects and insufficient anti-tumor immune response. null Intratumoral...